Karyopharm reports second quarter 2023 financial results and highlights recent company progress

– achieved second quarter 2023 total revenue of $37.6 million and u.s. xpovio® (selinexor) net product revenue of $28.5 million – –  maintains full year 2023 total revenue guidance of $145 million to $160 million, including u.s. xpovio net product revenue guidance of $110 million to $125 million – – announces ~20% workforce reduction enhancing financial strength; further reduces full year 2023 non-gaap r&d and sg&a expense guidance to $240 million to $255 million; cash runway into late 2025 – –initiated pivotal phase 3 study of xpo1 inhibitor selinexor and ruxolitinib in jak inhibitor (jaki) naÏve myelofibrosis in june 2023 and received fast track designation from us fda – – announced long-term exploratory subgroup analyses presented at asco plenary providing further rationale for xport-ec-042, the company's ongoing pivotal phase 3 study in endometrial cancer – – conference call scheduled for today at 8:00 a.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking